Evidence mapPaperPMID 35373328Full record

SynthesisCardiology journal2024

Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients.

Eryka Karbowska, Damian Swieczkowski, Aleksandra Gasecka, Michal Pruc, Kamil Safiejko, Jerzy R Ladny, Tomasz Kopiec, Milosz J Jaguszewski, Krzysztof J Filipiak, Zubaid Rafique and 1 more

Open access · goldAbstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Cardiology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Eryka KarbowskaDepartment of CT and MR Radiology, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland.ORCID 0000-0001-8469-9485
Damian SwieczkowskiDepartment of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Gdańsk, Poland.ORCID 0000-0002-5648-4652
Aleksandra GaseckaFirst Chair and Department of Cardiology, Medical University of Warsaw, Poland.ORCID 0000-0001-5083-7587
Michal PrucResearch Unit, Polish Soceity of Disaster Medicine, Warsaw, Poland.ORCID 0000-0002-2140-9732
Kamil SafiejkoColorectal Cancer Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland.ORCID 0000-0003-0373-9911
Jerzy R LadnyDepartment of Emergency Medicine, Medical University of Bialystok, Bialystok, Poland.ORCID 0000-0003-4167-1962
Tomasz KopiecFirst Chair and Department of Cardiology, Medical University of Warsaw, Poland.ORCID 0000-0003-1056-6385
Milosz J Jaguszewski1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.ORCID 0000-0003-2032-7484
Krzysztof J FilipiakInstitute of Clinical Science, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.ORCID 0000-0002-6563-0877
Zubaid RafiqueHenry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-4176-5988
Lukasz SzarpakInstitute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland. lukasz.szarpak@gmail.com.ORCID 0000-0002-0973-5455
Medical University of Białystok · PLGdańsk Medical University · PLMedical University of Warsaw · PLBaylor College of Medicine · USFoundation for Polish Science · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStatin use in many studies is related to the improvement of a patients' condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.

methodsPubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI).

resultsA total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72-0.96; I² = 84%; p = 0.01).

conclusionsIn summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsPancreatic NeoplasmsHumansIncidenceProtective FactorsRisk AssessmentRisk FactorsHydroxymethylglutaryl-CoA Reductase Inhibitorsmeta-analysispancreatic cancerpancreatic malignancyriskstatinsystematic review

Identifiers

PMID35373328
PMCPMC11076033
OpenAlexW4225919223

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.